Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.60
  • Today's Change-0.47 / -11.55%
  • Shares traded282.00
  • 1 Year change-43.93%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 20:49 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

  • Revenue in USD (TTM)7.46m
  • Net income in USD-64.90m
  • Incorporated2004
  • Employees168.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CytomX Therapeutics Inc119.18m16.53m132.46m120.008.60--7.131.110.19780.19781.53-0.46490.5684--16.71993,150.007.89-21.5326.77-32.32----13.87-100.38--------90.3811.2199.43---26.01--
Gossamer Bio Inc0.00-172.58m133.47m135.00--4.99-----1.05-1.050.000.11810.00----0.00-72.02-57.43-85.67-64.38-----------14.730.8854------21.61------
I-Mab ADR3.82m-202.40m134.09m220.00--0.5639--35.12-2.43-2.430.04592.940.0083----17,352.01-43.84-35.99-53.14-42.08100.00---5,302.03-496.71---42.630.0171--112.48-12.4641.54---4.66--
Tevogen Bio Holdings Inc0.00-67.33k134.14m17.00---------0.0004-0.00040.00-0.0045------0.00-------------------8.191.74------99.69------
Corvus Pharmaceuticals Inc0.00-24.86m135.11m28.00--3.17-----0.5113-0.51130.000.68040.00----0.00-50.58-38.31-59.70-43.34-----------12.880.00------34.57---37.45--
Syros Pharmaceuticals Inc6.98m-144.49m136.31m68.00--9.05--19.53-5.01-5.010.22440.56330.0411----102,661.80-84.98-54.44-103.51-64.32-----2,069.80-772.82----0.7332---33.2337.12-73.87---27.78--
Molecular Partners AG (ADR)7.46m-64.90m138.09m168.00--0.6332--18.52-1.97-1.970.22655.69------44,390.41---11.83---14.69--99.28-870.22-45.30----0.0195---96.29-7.43-152.59---1.40--
Global Pharmatech Inc.3.18m-2.24m138.32m217.00--1.02--43.51-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Rapt Therapeutics Inc0.00-118.05m139.55m126.00--1.07-----3.07-3.070.003.760.00----0.00-58.42-46.30-65.33-49.97-------3,522.72----0.00---100.00---39.31---20.31--
Scpharmaceuticals Inc17.63m-57.71m140.97m135.00--5.74--8.00-1.49-1.490.45450.68140.17130.75664.02130,607.40-56.07-38.23-62.13-42.3171.69---327.29-1,360.165.44-16.600.6159-------48.79------
FitLife Brands Inc58.51m7.30m141.12m37.0020.754.8019.042.411.481.4811.876.391.203.8727.131,581,351.0015.0326.4019.3733.9241.5542.0912.4817.650.517712.320.3582--82.9725.2819.5867.31----
Cardiff Oncology Inc610.00k-40.25m142.22m31.00--2.33--233.15-0.901-0.9010.01371.360.0068--1.1419,677.42-44.55-31.24-50.10-33.56-----6,594.92-7,819.23----0.00--26.425.22-7.07--157.91--
Vaxart Inc8.89m-81.74m144.12m109.00--2.58--16.22-0.5431-0.54310.0590.31550.0813--21.6781,513.76-74.81-49.60-86.63-54.86-----920.00-1,398.00----0.0705--6,796.2612.1523.47--21.49--
Repare Therapeutics Inc97.86m-45.69m147.71m179.00--0.6313--1.51-1.10-1.102.305.510.3265--9.22546,698.30-15.25-23.40-18.73-26.37-----46.69-162.76----0.00---61.21---222.91--27.16--
Veru Inc13.48m-35.82m147.85m189.00--3.27--10.97-0.3465-0.34650.12670.30890.18981.423.8671,318.68-50.43-42.91-76.84-54.4134.1372.41-265.74-104.964.22--0.177---58.590.5394-10.84--67.39--
Context Therapeutics Inc0.00-21.32m148.50m5.00--3.74-----1.34-1.340.000.52880.00----0.00-99.14---114.72--------------0.00-------61.53------
Data as of May 31 2024. Currency figures normalised to Molecular Partners AG's reporting currency: US Dollar USD

Institutional shareholders

2.60%Per cent of shares held by top holders
HolderShares% Held
BVF Partners LPas of 31 Mar 2024443.22k1.22%
Suvretta Capital Management LLCas of 31 Mar 2024400.00k1.10%
Tang Capital Management LLCas of 31 Mar 2024100.00k0.28%
RBC Capital Markets LLC (Investment Management)as of 31 Mar 20241.50k0.00%
Morgan Stanley & Co. LLCas of 31 Mar 2024367.000.00%
UBS Securities LLCas of 31 Mar 2024326.000.00%
RhumbLine Advisers LPas of 31 Mar 2024269.000.00%
Qube Research & Technologies Ltd.as of 31 Mar 202416.000.00%
JPMorgan Securities LLC (Investment Management)as of 31 Mar 20240.000.00%
G1 Execution Services LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.